A Phase 1 Study of HMPL-306 in Locally Advanced Solid Tumors with IDH mutations

2024-516370-30-00 Protocol 2020-306-GLOB2 Human pharmacology (Phase I) - Other Ended

Start 9 Feb 2021 · End 28 Feb 2025 · Status Ended · 1 EU/EEA countries · 2 sites · Protocol 2020-306-GLOB2

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 42
Countries 1
Sites 2

- Locally advanced or metastatic solid tumors - Cholangiocarcinoma - Skeletal chondrosarcoma - Low-grade glioma - Any other solid tumor harboring an IDH mutation

Key facts

Sponsor
Hutchmed Ltd.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
9 Feb 2021 → 28 Feb 2025
Decision date (initial)
2024-09-04
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-516370-30-00
EudraCT number
2020-003729-44
ClinicalTrials.gov
NCT04762602

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

- Locally advanced or metastatic solid tumors - Cholangiocarcinoma - Skeletal chondrosarcoma - Low-grade glioma - Any other solid tumor harboring an IDH mutation

VersionLevelCodeTermSystem organ class
21.1 LLT 10065252 Solid tumor 10029104
27.0 PT 10008593 Cholangiocarcinoma 100000004864
20.0 PT 10018338 Glioma 100000004864
21.1 PT 10008734 Chondrosarcoma 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Hutchmed Ltd.

Sponsor organisation
Hutchmed Ltd.
Address
Building 4, 720 Cailun Road, China (Shanghai) Pilot Free Trade Zone 720 Cailun Road China (Shanghai) Pilot Free Trade Zone
City
Shanghai
Postcode
201203
Country
China

Scientific contact point

Organisation
Hutchmed Ltd.
Contact name
William Schelman

Public contact point

Organisation
Hutchmed Ltd.
Contact name
William Schelman

Locations

1 EU/EEA country · 2 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ended 24 2
Rest of world
United States
18

Investigational sites

Spain

2 sites · Ended
Hospital Universitari Vall D Hebron
Oncology, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Hospital Universitario 12 De Octubre
Oncology, Avenida De Cordoba Sn, 28041, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2021-02-09 2025-02-27 2021-03-26 2023-08-08

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-09-02 Spain Acceptable with conditions
2024-09-04
2024-09-04